Replimune Group, Inc. is a pharmaceutical company based in the United States that specializes in developing cutting-edge oncolytic immunotherapies for cancer treatment. With an ESG score of 27.5, the company is classified as a medium risk investment. Replimune Group Inc utilizes its proprietary RPx platform, which is based on an engineered strain of herpes simplex virus 1, to create product candidates aimed at activating the immune system against solid tumors. The company's pipeline includes promising products such as RP1, RP2, and RP3.